Title
A naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment

Permalink
https://escholarship.org/uc/item/8c49557b

Journal
Journal of Clinical Psychiatry, 75(12)

ISSN
0160-6689

Authors
Zorick, T
Mandelkern, MA
Brody, AL

Publication Date
2014-12-01

DOI
10.4088/JCP.14m09012

Peer reviewed
A Naturalistic Study of the Association Between Antidepressant Treatment and Outcome of Smoking Cessation Treatment

Todd Zorick, MD, PhD; Mark A. Mandelkern, MD, PhD; and Arthur L. Brody, MD

ABSTRACT

Objective: Psychiatric, medical, and substance use comorbidities are highly prevalent among smokers, and many of these comorbidities have been found to be associated with reduced rate of success in clinical trials for smoking cessation. While much has been established about the best available treatments from these clinical trials, little is known about the effect of concomitant psychiatric medications on quit rates in smoking cessation programs. On the basis of results in populations with tobacco dependence and other substance use disorders, we hypothesized that smokers taking antidepressants would have a lower rate of quitting in an outpatient smoking cessation program.

Method: We performed a naturalistic chart review of veterans (N = 144) enrolled in the Veterans Affairs Greater Los Angeles Mental Health Clinic Smoking Cessation Program from March 2011 through July 2013, who met DSM-IV-TR criteria for nicotine dependence. The primary outcome was smoking cessation with treatment, as evidenced by a patient report of at least 1 week of abstinence and an exhaled carbon monoxide level of ≤6 ppm (if available) at the end of acute treatment, with comparators including concomitant psychotropic medication treatment, psychiatric and medical comorbidities, and the presence of a substance use disorder history. We utilized stepwise binary logistic regression as the main statistical technique.

Results: We found that current antidepressant treatment (P = .003) and history of substance use disorder (P = .01) (particularly cocaine [P = .02]) were associated with a lower rate of quitting smoking. Furthermore, the association between antidepressant treatment and reduced rate of smoking cessation was primarily seen in patients with a history of substance use disorder (P = .003).

Conclusions: While preliminary, these results suggest an important clinical interaction meriting future study. If these findings are confirmed, clinicians may want to consider the risk of reduced ability to quit smoking in patients with a history of substance use disorder who are taking antidepressants.

Antidepressant treatment is associated with a reduced rate of smoking cessation in a veteran-based smoking cessation clinic setting.

The detrimental effect of antidepressant treatment on smoking cessation outcome was seen primarily in those patients with a history of substance use disorders.

If these findings are confirmed, clinicians may want to consider the risk of reduced ability to quit smoking in patients with a history of substance use disorder who are taking antidepressants.

Participants were included in this chart review if they showed at least minimal participation in the clinic by attending at least 2 clinic sessions within 60 days with medication treatment for smoking cessation or at least 3 clinic sessions without medication treatment. A participant was considered to have ended treatment if he or she was absent from the clinic for more than 60 days. Participants were considered to have quit smoking if they had reported >7 days of smoking abstinence along with exhaled CO levels of ≤6 ppm (when available) at the end of acute (typically 3- to 4-month) treatment. If a participant had multiple clinic quit attempts during the study time frame, only the longest period of treatment was included in this review. Exclusionary criteria for the study were insufficient clinical information (eg, missing documentation of prescribed medications); any other treatment for smoking within the last 30 days prior to clinic entry; smoking fewer than 5 cigarettes per day on entry into clinic; treatment still ongoing as of July 2013; smoking pipes, cigars, or rolled tobacco; primarily using chewing tobacco; or starting or stopping psychotropic medication use (aside from bupropion) during the course of smoking cessation treatment.

Comorbid Medical and Psychiatric Conditions and Medication Treatment

Current and past medical and psychiatric diagnoses (including histories of substance use disorder) were obtained from the participants’ electronic medical records. For documentation of the primary substance use disorder (when present), we first surveyed their current and past computer health record problem lists, then reviewed any prior treatment episodes for which a history of substance use disorder was documented (including emergency room visits, inpatient hospitalizations, substance use disorder treatment episodes). Diagnoses and adjunctive medication treatments were included in the analysis if they represented >5% of the sample.

Antidepressants included therapeutic doses of selective serotonin reuptake inhibitors (such as fluoxetine), TCAs (such as amitriptyline), and atypical antidepressants (such as nefazodone, mirtazapine, and trazodone). Low-dose trazodone (≤150 mg/d) for insomnia was not counted as antidepressant treatment for the purposes of this study, as it has not shown efficacy as an antidepressant in that dose range. Antipsychotics included both older typical and newer atypical antipsychotics. Mood stabilizers included lithium, carbamazepine, valproate, and lamotrigine at therapeutic doses.

Statistical Analysis

Statistical analyses were accomplished using R version 2.13 (R Core Team: Vienna, Austria, 2012) and IBM SPSS version 21.0 (IBM: Armonk, New York, 2012). Analysis of variance and Fisher exact tests were used to assess for potential confounding factors based on the clinical data. We utilized a stepwise binary logistic regression to assess for the effect of psychotropic medication treatment while accounting for...
Table 1. Demographics and Clinical Characteristics

<table>
<thead>
<tr>
<th>Category</th>
<th>Quit(^a)</th>
<th>Not Quit(^b)</th>
<th>(P)</th>
<th>(Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sample (N = 144)</td>
<td>62 (43)</td>
<td>82 (57)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>56.3 (11.0)</td>
<td>55.3 (9.0)</td>
<td>.58</td>
<td></td>
</tr>
<tr>
<td>BDI score, (n = 70)</td>
<td>5.2 (3.8)</td>
<td>5.5 (4.6)</td>
<td>.79</td>
<td></td>
</tr>
<tr>
<td>Carbon monoxide level, ppm (n = 52)</td>
<td>9.7 (5.0)</td>
<td>14.8 (7.7)</td>
<td>.03*</td>
<td></td>
</tr>
<tr>
<td>No. of cigarettes/d</td>
<td>15.6 (6.7)</td>
<td>17.3 (9.6)</td>
<td>.24</td>
<td></td>
</tr>
<tr>
<td>No. of weeks in treatment</td>
<td>13.1 (11.0)</td>
<td>10.3 (10.3)</td>
<td>.11</td>
<td></td>
</tr>
<tr>
<td>No. of sessions attended</td>
<td>7.8 (4.8)</td>
<td>6.7 (5.2)</td>
<td>.19</td>
<td></td>
</tr>
<tr>
<td>FTND score (n = 71)</td>
<td>5.5 (1.7)</td>
<td>5.3 (2.0)</td>
<td>.79</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>21 (34)</td>
<td>31 (38)</td>
<td>.82</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>56 (90)</td>
<td>80 (98)</td>
<td>.13</td>
<td></td>
</tr>
<tr>
<td>Psychiatric/SUD history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any SUD</td>
<td>36 (58)</td>
<td>64 (78)</td>
<td>.01*</td>
<td></td>
</tr>
<tr>
<td>Alcohol</td>
<td>13 (21)</td>
<td>29 (35)</td>
<td>.07</td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td>6 (10)</td>
<td>21 (26)</td>
<td>.02*</td>
<td></td>
</tr>
<tr>
<td>Opiate</td>
<td>9 (15)</td>
<td>4 (5)</td>
<td>.08</td>
<td></td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>2 (3)</td>
<td>7 (9)</td>
<td>.3</td>
<td></td>
</tr>
<tr>
<td>Multiple SUDs</td>
<td>5 (8)</td>
<td>4 (5)</td>
<td>.5</td>
<td></td>
</tr>
<tr>
<td>Posttraumatic stress disorder</td>
<td>16 (26)</td>
<td>23 (28)</td>
<td>.85</td>
<td></td>
</tr>
<tr>
<td>Psychosis</td>
<td>11 (18)</td>
<td>15 (18)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>19 (31)</td>
<td>30 (37)</td>
<td>.48</td>
<td></td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>10 (16)</td>
<td>12 (15)</td>
<td>.82</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>8 (13)</td>
<td>8 (10)</td>
<td>.6</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>18 (29)</td>
<td>9 (11)</td>
<td>.01*</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>36 (58)</td>
<td>45 (55)</td>
<td>.74</td>
<td></td>
</tr>
<tr>
<td>Liver disease</td>
<td>8 (13)</td>
<td>6 (7)</td>
<td>.27</td>
<td></td>
</tr>
<tr>
<td>Lung disease</td>
<td>14 (23)</td>
<td>25 (30)</td>
<td>.35</td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>30 (48)</td>
<td>32 (39)</td>
<td>.31</td>
<td></td>
</tr>
<tr>
<td>Adjunctive medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antidepressants</td>
<td>14 (23)</td>
<td>39 (48)</td>
<td>.003*</td>
<td></td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>16 (26)</td>
<td>29 (35)</td>
<td>.28</td>
<td></td>
</tr>
<tr>
<td>Mood stabilizers</td>
<td>7 (11)</td>
<td>6 (7)</td>
<td>.56</td>
<td></td>
</tr>
<tr>
<td>Opiates</td>
<td>17 (27)</td>
<td>16 (20)</td>
<td>.36</td>
<td></td>
</tr>
<tr>
<td>Sedatives</td>
<td>4 (6)</td>
<td>5 (6)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Nicotine replacement therapy</td>
<td>49 (79)</td>
<td>59 (72)</td>
<td>.44</td>
<td></td>
</tr>
<tr>
<td>Bupropion</td>
<td>11 (18)</td>
<td>25 (30)</td>
<td>.12</td>
<td></td>
</tr>
<tr>
<td>Varenicline</td>
<td>13 (21)</td>
<td>10 (12)</td>
<td>.07</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Listed statistical contrasts are uncorrected for multiple comparisons.

\(^b\)Values reported as n (%) for categorical variables and as mean (SD) for continuous variables.

\(^c\)Analysis of variance was used for continuous variables, and the Fisher exact test was used for categorical variables.

\(^d\)P values indicating a statistically significant comparison.

Abbreviations: BDI = Beck Depression Inventory, FTND = Fagerström Test for Nicotine Dependence, NA = not applicable, SUD = substance use disorder.

RESULTS

Demographics and Clinical Characteristics

A total of 417 patients were enrolled in the clinic from March 2011 through July 2013. Of these, 205 met criteria for treatment engagement, as defined above. Seventeen patients were repeat patients, and thus excluded, while 6 patients were excluded due to insufficient clinical information available. Four patients were excluded for having been in another smoking cessation program within 30 days of entry to the clinic, 13 patients were excluded for smoking fewer than 5 cigarettes per day, 8 were excluded for smoking non-cigarette forms of tobacco or using primarily chewing tobacco, 10 patients were excluded because their treatment was ongoing as of the date of chart review, and 3 patients were excluded because they either stopped or started psychotropic medication treatment during treatment for smoking cessation. Overall, 144 patient charts met full study criteria (Table 1).

Table 1 presents an overview of the demographics of the patient population, broken down by whether or not they were able to quit smoking during clinic treatment. Quitters did not differ from nonquitters in terms of mean age, intake BDI score, reported cigarettes per day, number of weeks in treatment, number of sessions attended, entry FTND score, ethnicity, or gender distribution. Mean (SD) intake CO level was higher for nonquitters (14.8 [7.7] ppm) than for quitters (9.7 [5.0] ppm) in the participants for which this value was available (\(F_{1,50} = 4.8, P = .03\); Table 1).

With regard to psychiatric and medical histories of the participants, quitters and nonquitters did not differ in the frequency of diagnoses of posttraumatic stress disorder, psychotic disorders (including schizophrenia and schizoaffective disorders), major depression, bipolar disorders (either I, II, or not otherwise specified), cardiac disease, hypertension, liver disease (including chronic hepatitis and cirrhosis), lung disease (including emphysema, chronic obstructive pulmonary disease, and asthma), or chronic back pain (Table 1). However, nonquitters had a higher rate of comorbid substance use disorder history than quitters (78% vs 58%; \(P = .01\); Table 1). When comparisons were broken down by primary substance use disorder, a history of cocaine use disorder was present more frequently in nonquitters than in quitters (26% vs 10%; \(P = .02\); Table 1). Furthermore, there was a trend to significance for quitters to have a lower rate of alcohol use disorder history than nonquitters (21% vs 35%; \(P = .07\); Table 1). There were no differences between quitters and nonquitters in the overall rate of methamphetamine use disorder or multiple substance use disorders (Table 1). By contrast, there was a trend for quitters to have a higher rate of opiate use disorder than nonquitters (15% vs 5%; \(P = .08\); Table 1). Quitters were also more likely than nonquitters to have a history of diabetes mellitus (29% vs 11%; \(P = .01\)). In terms of other adjunctive medications, quitters did not differ from nonquitters in the rate of concomitant prescription opiate treatment or sedative-hypnotic medication or in the use of nicotine replacement therapy or bupropion as smoking cessation treatments (Table 1). However, there was a strong trend for quitters to be more likely to be taking varenicline for smoking cessation than nonquitters (21% vs 12%; \(P = .07\); Table 1).

Psychotropic Medication Treatment and Smoking Cessation Rates

To assess whether antidepressant treatment status continued to exhibit a significant effect after taking into account possible confounding factors, we performed a series of stepwise binary logistic regressions with quit status as the dependent variable (Figures 1 and 2; Tables 2 and 3). For the binary logistic regression with quit status as the dependent variable (Figures 1 and 2; Tables 2 and 3).
treatment, a smaller proportion of participants taking antidepressants quit (26% [14/53]) than participants not taking antidepressants (53% [48/91]; \( P = .0025 \), Figure 1). By contrast, there was no significant difference in the proportion of patients quitting while taking antipsychotic (36% [16/45]; \( P = .22 \)) or mood stabilizer medications (54% [7/13]; \( P = .41 \)) (Figure 1).

To provide convincing evidence that the deleterious effect of antidepressant treatment was not due to psychiatric history, we also performed stepwise binary logistic regressions with diabetes, psychiatric diagnoses, and psychotropic treatments as variables (Table 2). Antidepressant treatment remained the only significant mediator treatment variable (\( P = .003 \)), though a strong trend was observed for antipsychotic treatment (\( P = .073 \); Table 2). Subsequently, we looked at possible substance use disorder confounders and found that the effect of adding antidepressant treatment status remained significant even after incorporating either history of substance use disorder (\( P = .015 \)) or cocaine use disorder (\( P = .010 \)), together with diabetes mellitus, into the model (Table 3). Analysis of the interaction of antidepressant treatment with either substance use disorder or cocaine use disorder reduced the overall quality of the model fit due to collinearity between substance use disorder and antidepressant treatment status \( (R^2 = 0.25; \text{see next section}) \), while there were no significant effects of the interactions between antidepressant treatment and diabetes history.

**Smoking Cessation Quit Rates, Antidepressant Treatment, and Substance Use Disorder History**

On the basis of the studies showing that substance use disorders are associated with poor response to antidepressant
treatment, along with the collinearity we observed between substance use disorder history and antidepressant treatment, we tested the hypothesis that the negative effect of antidepressant treatment on smoking cessation quit rate would be seen primarily in patients with a history of substance use disorder (Figure 2). We separated the sample into patients with (n = 101) and without (n = 43) substance use disorder history and compared the quit rate among those participants taking antidepressants in each category. We again utilized a stepwise binary logistic regression with history of diabetes mellitus as a potential confounding factor. Among patients with a history of substance use disorder, those taking antidepressants (n = 8 [18%]) were less likely to quit smoking than those not taking antidepressants (n = 28 [49%]; P = .003; Figure 2). By contrast, in patients without a history of substance use disorder, there was no overall difference in quit rate between patients taking (n = 6 [67%]) or not taking (n = 20 [58%]) antidepressants after accounting for diabetes history (P = .82; Figure 2).

DISCUSSION
Antidepressant Treatment Is Associated With a Lower Rate of Smoking Cessation in a Naturalistic Clinic Setting

We found that antidepressant treatment among veterans with psychiatric and/or substance use disorder comorbidities was associated with a lower rate of smoking cessation, even after taking into account other possible confounding factors (Tables 2 and 3; Figure 2). These data support results from other recent clinical trials and naturalistic studies showing that concomitant antidepressant treatment reduces the rate of smoking cessation. Our results also support findings from other naturalistic treatment settings showing that antidepressant use is associated with a lower rate of subsequent smoking cessation, either in a smoking cessation treatment paradigm or in a cohort of medically ill outpatients not in treatment for tobacco dependence. These prior associational findings were ascribed variously to depressive symptoms or amotivation associated with antidepressant treatment; however, we found that baseline depressive symptoms did not differ between quitters and nonquitters, and there was no difference in either time spent in treatment or prevalence of diagnoses of either major depression or bipolar disorders in our cohort (Table 1). Therefore, neither baseline depressive symptoms nor treatment engagement nor psychiatric history is a good explanatory factor for the negative effect of antidepressant treatment on smoking cessation quit rate.

Antidepressants Reduce Smoking Cessation Treatment Efficacy in Patients With a History of Substance Use Disorders

Clinical trials of antidepressants for active smokers typically exclude participants with recent history of substance use disorder and do not keep track of how many have a more remote history of this disorder (eg, Saules et al). To our knowledge, our current findings represent the first report of the association of reduced smoking cessation efficacy in patients with a history of substance use disorder who are taking antidepressants. There are currently no accepted theories as to why antidepressant treatment is associated with reduced efficacy of treatment for the underlying substance use disorder (including smoking), but one possible explanation was found in a reanalysis of a placebo-controlled trial of sertraline for methamphetamine dependence. Participants who were taking sertraline demonstrated increased craving and use of methamphetamine as compared with all other participants. Therefore, there may be increased craving for tobacco and other substances of abuse with antidepressant treatment. However, further studies are needed to follow up on this preliminary finding and to better characterize this phenomenon.

Limitations

While our data are compelling, it is important to recognize study limitations. This was a naturalistic chart review study and therefore is capable of indicating only associations between possible explanatory variables and treatment outcomes, not causative relationships. Our sample of veterans is mostly male and thus may not generalize to populations of treatment-seeking female smokers. Furthermore, the sample size was relatively small, especially for subpopulations (eg, individuals with opiate or cocaine use disorder). Psychiatric disorders (including substance use disorders) were based on clinician report via electronic records and therefore may not have been determined with a standard rating scale or standard questions using DSM criteria. There is also a possibility of bias present in the historical information available from electronic medical records about diagnostic histories of the patients by participant reports or treating clinicians’ interpretations. While there is no a priori reason to assume that the pattern of missing information from patients about intake CO levels or BDI or FTND scores was anything other than random, this remains a possible source of bias as well.

CONCLUSIONS

In our sample of urban veteran smokers with extensive psychiatric, medical, and substance use disorder comorbidities, antidepressant use was associated with a lower rate of smoking cessation in an outpatient treatment program. By comparison, the same sample did not reveal an effect of baseline depressive symptoms, demographic factors, psychiatric disorders (aside from substance use disorders), medical conditions (aside from diabetes mellitus), antipsychotic usage, or mood stabilizer usage. The reduction by antidepressants of the efficacy of the smoking cessation treatment was seen primarily in patients with a history of substance use disorder. While the underlying cause of this phenomenon remains unknown, these results, taken together with those of other studies demonstrating a similar effect both in smoking cessation treatment and in treatment studies for other substances of abuse, indicate a clinically important phenomenon worthy of additional research. If
these finding are borne out by future research, then the possible detrimental effects of antidepressants on the ability of patients with a history of substance use disorder to quit smoking should be included in the risk/benefit analysis carried out by treating physicians.

**Drug names:** bupropion (Wellbutrin, Aplenzin, and others), carbamazepine (Carbatrol, Equetro, and others), fluoxetine (Prozac and others), lamotrigine (Lamictal and others), lithium (Lithobid and others), mirtazapine (Remeron and others), sertraline (Zoloft and others), trazodone (Oleptro and others), varenicline (Chantix).

**Author affiliations:** Departments of Psychiatry (Drs Zorick and Brody) and Imaging (Dr Mandelkern), VA Greater Los Angeles Healthcare System; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Drs Zorick and Brody); and Department of Physics, University of California, Irvine (Dr Mandelkern).

**Potential conflicts of interest:** None reported.

**Funding/support:** Dr Zorick is supported by a VA Career Development Award (101 BX007080); Dr Brody receives grant funding from the National Institute on Drug Abuse (R01 DA20872), the Tobacco-Related Disease Research Program (23XT-0002), and a VA Merit Review Award (I01 BX007080). Dr Brody is supported by a VA Career Development Award (I01 BX007080) and is affiliated with the National Institute on Drug Abuse (R01 DA20872), the Tobacco-Related Disease Research Program (23XT-0002), and Department of Physics, University of California, Irvine (Dr Mandelkern).

**Role of the sponsors:** The funding agencies had no role in the conduct or publication of the study.

**REFERENCES**


